Skip to main content

Table 1 The clinic-pathological characteristics of patients in various lymph node yield groups

From: How does lymph node yield affect survival outcomes of stage I and II colon cancer?

 

Total

LN<12

LN12-19

LN≥20

p

N = 659

N = 227

N = 268

N = 164

Age at surgery

71.8 ± 12.1

72.1 ± 11.46

73.42 ± 11.14

68.51 ± 13.81

< 0.001

Gender

 Male

363 (55.1%)

132 (58.1%)

155(57.89%)

76(46.3%)

0.034

 Female

296 (44.9%)

95(41.9%)

113(42.2%)

88 (53.7%)

ASA

 1–2

431 (65.4%)

144(66.1)

166(63.6)

121(80.1)

0.002

 ≥ 3

199 (30.2%)

74(33.9)

95(36.4%)

30(19.9%)

CCI

2.47 ± 0.8

2.4 ± 0.8

2.6 ± 0.8

2.4 ± 0.7

0.105

Preoperative CEA

12.5 ± 40.6

8.7 ± 30.6

13.1 ± 39.1

16.7 ± 53.3

0.245

Year of surgery

 2003–2007

329 (49.9%)

151 (66.5%)

110 (41.0%)

68 (41.5%)

< 0.001

 2008–2012

330 (50.1%)

76 (33.5%)

158 (59.0%)

96 (58.5%)

Type of surgery

 Elective

555 (84.2%)

187 (82.4%)

231 (86.2%)

137 (83.5%)

0.491

 Emergency

104 (15.8%)

40 (17.6%)

37 (13.8%)

27 (16.5%)

Surgical approach

 Laparoscopic

304 (46.1%)

90 (39.8%)

137 (51.3%)

77 (47.0%)

0.011

 Open

335 (50.8%)

134 (59.3%)

121(45.3%)

80 (48.8%)

 Laparoscopic converted open

18 (2.7%)

2 (0.9%)

9 (3.4%)

7 (4.3%)

Site of tumour

 Caecum

72 (10.9%)

24 (10.6%)

31 (11.6%)

17 (10.4%)

0.914

 Ascending colon

97 (14.7%)

28 (12.3%)

45 (16.8%)

24 (14.6%)

 Hepatic flexure

63 (9.6%)

17 (7.5%)

27 (10.1%)

19 (11.6%)

 Transverse colon

93 (14.1%)

33 (14.5%)

37 (13.8%)

23 (14.0%)

 Splenic flexure

31 (4.7%)

10 (4.4%)

11 (4.1%)

10 (6.1%)

 Descending colon

67 (10.2%)

28 (12.3%)

26 (9.7%)

13 (7.9%)

 Sigmoid colon

236 (35.8%)

87 (38.3%)

91 (33.9%)

7 (35.3%)

Type of resection

 Right sided

323 (49.0%)

99 (43.6)

139 (51.9%)

85 (51.8%)

0.159

 Left sided

306 (46.4%)

120 (52.9%)

117 (43.7%)

69 (42.1%)

 Subtotal

30 (4.6%)

8 (3.5%)

12 (4.5%)

10 (6.1%)

Perforation

 Yes

29 (4.4%)

10(4.4%)

13(4.9%)

6(3.7%)

0.842

 No

630 (95.6%)

217(95.6%)

255(95.1%)

158(96.3%)

Obstruction

 Yes

114 (17.3%)

37(16.4%)

44(16.4%)

33 (20.2%)

0.531

 No

543 (82.4%)

189(83.6%)

224(83.6%)

130(79.8%)

Tumour size

42.1 ± 26.6

37.1 ± 21.9

42.6 ± 27.5

48.0 ± 29.7

< 0.001

T stage

 1&2

155 (23.6%)

68 (30.0%)

61 (22.8%)

26 (15.9%)

0.005

 3&4

503 (76.4%)

159 (70.0%)

206 (77.2%)

138 (84.1%)

Differentiation

 Well

58 (8.8%)

24 (11.3%)

24 (9.2%)

10 (6.2%)

0.563

 Moderate

533 (80.9%)

176 (83.0%)

216 (83.1%)

141 (87.6%)

 Poor

39 (5.9%)

11 (5.2%)

19 (7.3%)

9 (5.6%)

Perineural invasion

 Yes

40 (6.1%)

15 (6.8%)

15 (5.7%)

10 (6.1%)

0.888

 No

604 (91.7%)

205 (93.2%)

246 (94.3%)

153 (93.9%)

LVP

 Yes

92 (14.0%)

39 (17.3%)

39 (14.8%)

14 (8.6%)

0.049

 No

559 (84.8%)

186 (82.7%)

225 (85.2%)

148 (91.4%)

Mucinous

 Yes

63 (9.6%)

16(7.2%)

31 (11.7%)

16 (10.0%)

0.383

 No

583 (88.5%)

205 (92.8%)

234 (88.0%)

144 (90.0%)

Signet

 Yes

2 (0.3%)

221 (100%)

263 (99.2%)

160 (100.0%)

0.236

 No

644 (97.7%)

0 (0%)

2 (0.8%)

0 (0%)

Margin

 Involved

1 (0.4%)

0 (0.0%)

1 (0.6%)

2 (0.3%)

0.481

 Clear

226 (99.6%)

268 (100.0%)

163 (99.4%)

657 (99.7%)

Adjuvant chemotherapy

 Yes

36 (15.9%)

35 (13.1%)

35 (21.3%)

106 (16.1%)

0.075

 No

191 (84.1%)

233 (86.9%)

129 (78.7%)

553 (83.9%)

  1. ASA American Society of Anaesthesiologist grade, CCI Charlson co-morbidity index, CEA carcino-embryonic antigen, LVP lymphovascular permeation